Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Eli Lilly reports topline results from two global phase III ramucirumab studies

Sep. 30, 2013

Mologen submits MGN-1703 IND application with FDA

Sep. 27, 2013

Bio-Matrix Scientific provides update on dCellVax for breast cancer

Sep. 27, 2013

Merck KGaA to renew testing of lung cancer vaccine

Sep. 27, 2013

Trastuzumab emtansine receives committee recommendation in E.U.

Sep. 23, 2013

OncoMed Pharmaceuticals begins phase Ib/II trial of demcizumab in ovarian cancer

Sep. 23, 2013

Chugai gains Japanese approval for HER2-targeted antibody-drug conjugate

Sep. 20, 2013

Prima BioMed reports topline data from phase II CVac trial

Sep. 20, 2013

Agenus reports follow-on phase II data for brain cancer vaccine

Sep. 19, 2013

Provenge obtains European approval

Sep. 18, 2013

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...